Elin Svensson
Universitetslektor vid Institutionen för farmaci; Farmakometri
- E-post:
- elin.svensson@farmaci.uu.se
- Besöksadress:
- Biomedicinskt Centrum BMC, Husargatan 3
- Postadress:
- Box 580
751 23 UPPSALA
Ladda ned kontaktuppgifter för Elin Svensson vid Institutionen för farmaci; Farmakometri
- CV:
- Ladda ned CV
- ORCID:
- 0000-0002-0093-6445
Mer information visas för dig som medarbetare om du loggar in.
Kort presentation
Min forskning är fokuserad på farmakometriska modeller applicerade inom Global Hälsa, främst med syftet att förbättra behandling av tuberkulos och HIV. Två huvudteman är biomarkörer som predikterar behandlingsresultat och optimering av läkemedelsdosering i barn. De flesta av mina projekt ingår i internationella samarbeten, t.ex. med IMPAACT, PanACEA och UNITE4TB. Jag har också en forskartjänst vid Radboud University Medical Center, Nederländerna.
Publikationer
Senaste publikationer
- Conjugated hyperbilirubinemia associated with accidental rifapentine overdose (2024)
- Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development (2023)
- New and Repurposed Drugs for the Treatment of Active Tuberculosis (2023)
- A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis (2023)
- Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents (2023)
Alla publikationer
Artiklar
- Conjugated hyperbilirubinemia associated with accidental rifapentine overdose (2024)
- Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development (2023)
- New and Repurposed Drugs for the Treatment of Active Tuberculosis (2023)
- A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis (2023)
- Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents (2023)
- Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis (2023)
- Power to identify exposure-response relationships in phase IIa pulmonary tuberculosis trials with multi-dimensional bacterial load modeling. (2023)
- Early bactericidal activity studies for pulmonary tuberculosis (2023)
- Physiologically-Based Pharmacokinetic Modelling to Predict the Pharmacokinetics and Pharmacodynamics of Linezolid in Adults and Children with Tuberculous Meningitis (2023)
- Exposure and virologic outcomes of dolutegravir combined with ritonavir boosted darunavir in treatment-naive individuals enrolled in the Netherlands Cohort Study on Acute HIV infection (NOVA) (2023)
- Clinical standards for the management of adverse effects during treatment for TB (2023)
- Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis (2023)
- Model-based analysis of bactericidal activity and a new dosing strategy for optimised-dose rifampicin (2023)
- Pharmacometrics - tools to assure optimal medicine use in low- and middle-income countries (2022)
- Clinical standards for the dosing and management of TB drugs (2022)
- Prediction of Maternal and Fetal Doravirine Exposure by Integrating Physiologically Based Pharmacokinetic Modeling and Human Placenta Perfusion Experiments (2022)
- Mycobacterium Growth Indicator Tube Time-To-Positivity Can Serve As an Early Biomarker of Treatment Response in Mycobacterium avium Complex Pulmonary Disease (2022)
- Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis (2022)
- Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis (2022)
- Pharmacogenetics of Between-Individual Variability in Plasma Clearance of Bedaquiline and Clofazimine in South Africa (2022)
- Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data (2022)
- Optimized Loading Dose Strategies for Bedaquiline When Restarting Interrupted Drug-Resistant Tuberculosis Treatment (2022)
- Prediction of Moxifloxacin Concentrations in Tuberculosis Patient Populations by Physiologically Based Pharmacokinetic Modeling (2022)
- Drug concentration at the site of disease in children with pulmonary tuberculosis (2022)
- Emerging data on rifampicin pharmacokinetics and approaches to optimal dosing in children with tuberculosis (2022)
- Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fibre system that simulates human plasma and epithelial lining fluid pharmacokinetics (2022)
- Population Pharmacokinetic and Concentration-QTc Analysis of Delamanid in Pediatric Participants with Multidrug-Resistant Tuberculosis (2022)
- Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline (2022)
- Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens (2022)
- Model-Predicted Impact of ECG Monitoring Strategies During Bedaquiline Treatment (2022)
- Adequate exposure of 50 mg dolutegravir in children weighing 20 to 40 kg outside of sub-Sahara Africa (2022)
- Pharmacometrics in tuberculosis (2022)
- Characterizing Absorption Properties of Dispersible Pretomanid Tablets Using Population Pharmacokinetic Modelling (2022)
- Effect of Clofazimine Concentration on QT Prolongation in Patients Treated for Tuberculosis (2021)
- The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary Tuberculosis (2021)
- A population pharmacokinetics analysis assessing the exposure of raltegravir once-daily 1200 mg in pregnant women living with HIV (2021)
- High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults (2021)
- Rethinking the Application of Pemetrexed for Patients with Renal Impairment (2021)
- Pharmacokinetics and safety of high-dose rifampicin in children with TB (2021)
- Relationship between Plasma and Intracellular Concentrations of Bedaquiline and Its M2 Metabolite in South African Patients with Rifampin-Resistant Tuberculosis (2021)
- Higher Dosing of Rifamycins Does Not Increase Activity against Mycobacterium tuberculosis in the Hollow-Fiber Infection Model (2021)
- Pharmacometrics meets statistics-A synergy for modern drug development (2021)
- An In Vitro Perspective on What Individual Antimicrobials Add to Mycobacterium avium Complex Therapies (2021)
- Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs (2021)
- Exposure–safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug‐resistant tuberculosis (2021)
- Increased bactericidal activity but dose-limiting intolerability at 50 mg.kg(-1) rifampicin (2021)
- Model-based assessment of the safety of community interventions with primaquine in sub-Saharan Africa (2021)
- A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis (2021)
- Normal fat mass cannot be reliably estimated in typical pharmacokinetic studies (2021)
- Constructing a representative in-silico population for paediatric simulations (2021)
- Clofazimine pharmacokinetics in patients with TB (2020)
- Probability of mycobactericidal activity of para-aminosalicylic acid with novel dosing regimens (2020)
- The pharmacokinetics of para-aminosalicylic acid and its relationship to efficacy and intolerance (2020)
- Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection (2020)
- Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease? (2020)
- Rifampicin can be given as flat-dosing instead of weight-band dosing (2020)
- Model-based meta-analysis of rifampicin exposure and mortality in Indonesian tuberculous meningitis trials (2020)
- Understanding the drug exposure-response relationship of bedaquiline to predict efficacy for novel dosing regimens in the treatment of multidrug-resistant tuberculosis (2020)
- Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis (2019)
- Protein binding of rifampicin is not saturated when using high-dose rifampicin (2019)
- A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria (2019)
- Auranofin Activity Exposes Thioredoxin Reductase as a Viable Drug Target in Mycobacterium abscessus (2019)
- Personalized Tuberculosis Treatment Through Model-Informed Dosing of Rifampicin (2019)
- Relative bioavailability of bedaquiline tablets suspended in water (2018)
- The Potential for Treatment Shortening With Higher Rifampicin Doses (2018)
- Evidence-Based Design of Fixed-Dose Combinations (2018)
- Greater Early Bactericidal Activity at Higher Rifampicin Doses Revealed by Modeling and Clinical Trial Simulations (2018)
- Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug resistant tuberculosis (2017)
- Modelling of mycobacterial load reveals bedaquiline's exposure-response relationship in patients with drug-resistant TB (2017)
- Evidence-based design of fixed-dose combinations (2017)
- Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs (2016)
- Pharmacokinetic Interactions for Drugs with a Long Half-Life-Evidence for the Need of Model-Based Analysis (2016)
- Population Pharmacokinetics of Bedaquiline and Metabolite M2 in Patients With Drug-Resistant Tuberculosis (2016)
- Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug (2015)
- Impact of Lopinavir-Ritonavir or Nevirapine on Bedaquiline Exposures and Potential Implications for Patients with Tuberculosis-HIV Coinfection (2014)
- Use of a linearization approximation facilitating stochastic model building (2014)
- Model-Based Estimates of the Effects of Efavirenz on Bedaquiline Pharmacokinetics and Suggested Dose Adjustments for Patients Coinfected with HIV and Tuberculosis (2013)
- Integration of data from multiple sources for simultaneous modelling analysis (2012)
- Modeling of mycobacterial load reveals bedaquiline’s exposure-response relationship in patients with drug-resistant tuberculosis
- Pharmacodynamic interaction of bedaquiline and delamanid co-administration on QTcF interval prolongation
Böcker
